title: Reply to C.G. Rusthoven et al.
authors.affiliation: Vattikuti Urology Institute and Center for Outcomes Research Analytics and Evaluation, Henry Ford Hospital, Detroit, MI.
authors.forename: Firas
authors.initials: F
authors.lastname: Abdollah
authors.affiliation: Mayo Clinic, Rochester, MN.
authors.forename: R Jeffrey
authors.initials: RJ
authors.lastname: Karnes
authors.affiliation: Urological Research Institute, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale San Raffaele, Milan, Italy.
authors.forename: Giorgio
authors.initials: G
authors.lastname: Gandaglia
authors.affiliation: Urological Research Institute, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale San Raffaele, Milan, Italy.
authors.forename: Nicola
authors.initials: N
authors.lastname: Fossati
authors.affiliation: Urological Research Institute, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale San Raffaele, Milan, Italy.
authors.forename: Francesco
authors.initials: F
authors.lastname: Montorsi
authors.affiliation: Urological Research Institute, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale San Raffaele, Milan, Italy briganti.alberto@hsr.it.
authors.forename: Alberto
authors.initials: A
authors.lastname: Briganti
mesh_terms: D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000401:mortality* / Q000532:radiotherapy*; D018714:Radiotherapy, Adjuvant / Q000379:methods*